Caspofungin for treatment of invasive aspergillosis in Germany: Results of a pre-planned subanalysis of an international registry

European Journal of Medical Research

Volumn 17, Issue 1, 2012, Pages

  Egerer, Gerlinde ^a   Reichert, Dietmar ^b,f   Pletz, Mathias W ^c,g   Kaskel, Peter ^d   Krobot, Karl J ^d   Maertens, Johan ^e  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b KLINIKUM OLDENBURG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Outcomes Research   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f Hämatologisch Onkologische Gemeinschaftspraxis   (Germany)

^g JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Caspofungin; Echinocandins; Invasive aspergillosis; Invasive fungal disease; Therapy

Indexed keywords

CASPOFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GERMANY; HUMAN; INVASIVE ASPERGILLOSIS; MALE; MONOTHERAPY; MULTICENTER STUDY; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; ASPERGILLUS; LUNG ASPERGILLOSIS; MIDDLE AGED; PATHOGENICITY; PATHOLOGY;

ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLUS; ECHINOCANDINS; GERMANY; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MIDDLE AGED;

EID: 84865744682     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-17-7     Document Type: Article

References (19)

1. Treatment of invasive fungal infections in cancer patients- recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H, Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, Kubin T, Penack O, Reichert D, Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G, Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Ann Hematol 2009 88 97 110 10.1007/s00277-008-0622-5 18853161
2. Patients at high risk of invasive fungal infections: when and how to treat. Rüping MJ, Vehreschild JJ, Cornely OA, Drugs 2008 68 1941 1962 10.2165/00003495-200868140-00002 18778118
3. Systemic fungal infections caused by Aspergillus species. Brakhage A, Curr Drug Targets 2005 6 875 886 10.2174/138945005774912717 16375671
4. Trendwende in der Mykosefrequenz bei hämatologischen Neoplasien: Obduktionsergebnisse von 1976 bis 2005. Donhuijsen K, Petersen P, Schmid KW, Dtsch Arztebl 2008 105 501 506
5. Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C, Bone Marrow Transplant 2011 46 709 718 10.1038/bmt.2010.175 20661235
6. Fachinformation CANCIDAS 50 mg/70 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung. MSD SHARP & DOHME GmbH (Haar, Juli 2009)
7. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. Maertens J, Egerer G, Shin W, Reichert D, Stek M, Chandwani S, Shivaprakash M, Viscoli C, BMC Infect Dis 2010 10 182 10.1186/1471-2334-10-182 20569436
8. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases, Clin Infect Dis 2002 34 7 14 10.1086/323335 11731939
9. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group, Clin Infect Dis 2004 39 1563 1571 10.1086/423381 15578352
10. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Bourque MR, Lupinacci RJ, Sable CA, DePauw BE, N Engl J Med 2004 351 1391 1402 10.1056/NEJMoa040446 15459300
11. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C, Bone Marrow Transplant 2010 45 1227 1233 10.1038/bmt.2009.334 20062093
12. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J, Infectious Disease Group of the EORTC, J Antimicrob Chemother 2009 64 1274 1281 10.1093/jac/dkp355 19841031
13. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F, Castelli M, Viale P, Fanin R, Eur J Haematol 2005 75 227 233 10.1111/j.1600-0609.2005.00500.x 16104879
14. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group, N Engl J Med 2002 347 408 415 10.1056/NEJMoa020191 12167683
15. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R, AmBiLoad Trial Study Group, Clin Infect Dis 2007 44 1289 1297 10.1086/514341 17443465
16. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J, Clin Infect Dis 2005 41 301 307 10.1086/431586 16007524
17. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, Krobot KJ, Gerth WC, Longitudinal Evaluation of Antifungal Drugs (LEAD I) Investigators, Clin Infect Dis 2006 43 29 e38 10.1086/505969 16838223
18. Combinations of antifungal agents in therapy-what value are they? Cuenca-Estrella M, J Antimicrob Chemother 2004 54 854 869 10.1093/jac/dkh434 15375111
19. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L, Cancer 2007 110 2740 2746 10.1002/cncr.23109 17941026